Merck & Co Archives -

Merck’s Keytruda flunks another prostate cancer test

Phil Taylor AstraZeneca, biliary tract cancer, Imfinzi, immuno-oncology, Keytruda, Merck & Co, Oncology, Prostate cancer 0 Comment

Prostate cancer has proved an elusive target for cancer immunotherapies, and Merck & Co’s checkpoint inhibitor Keytruda is

Merck’s Keytruda flunks another prostate cancer test

https://pharmaphorum.com/news/mercks-keytruda-flunks-another-prostate-cancer-test/

News/ News/ News/ Oncology/ R&D

Merck puts big bucks behind ADC alliance with China’s Kelun

Phil Taylor antibody-drug conjugate, Kelun-Biotech, Merck & Co, Oncology, partnering 0 Comment

Merck & Co’s efforts to diversify its cancer pipeline beyond immunotherapy blockbuster Keytruda have taken a big step

Merck puts big bucks behind ADC alliance with China’s Kelun

https://pharmaphorum.com/news/merck-puts-big-bucks-behind-adc-alliance-with-chinas-kelun/

News/ News/ News/ News/ Oncology/ Patients/ R&D

Merck and Moderna’s mRNA cancer vaccine aces its first efficacy trial

Phil Taylor cancer vaccine, immuno-oncology, melanoma, Merck & Co, Moderna, mRNA, mRNA vaccines, Oncology, personalisation 0 Comment

The mRNA technology that was deployed so effectively in vaccines against COVID-19 has now been found to offer

Merck and Moderna’s mRNA cancer vaccine aces its first efficacy trial

https://pharmaphorum.com/news/merck-and-modernas-mrna-cancer-vaccine-aces-its-first-efficacy-trial/

News/ News/ News/ Oncology/ R&D

GSK trumpets Jemperli vs Keytruda data in first-line NSCLC

Phil Taylor GSK, immuno-oncology, Jemperli, Keytruda, Merck & Co, Non-small cell lung cancer, Oncology 0 Comment

GSK says its PD-1 inhibitor Jemperli compared favourably with Merck & Co’s Keytruda in a head-to-head trial in

GSK trumpets Jemperli vs Keytruda data in first-line NSCLC

https://pharmaphorum.com/news/gsk-trumpets-jemperli-vs-keytruda-data-in-first-line-nsclc/

Cancer/ News/ News/ News/ Oncology/ Patients

AstraZeneca, MSD raise prostate cancer awareness with ‘Never Miss’ campaign

Nicole Raleigh AstraZeneca, campaign, early detection, Merck & Co, MSD, Never Miss, Oncology, Prostate cancer 0 Comment

A new global prostate cancer awareness campaign developed by biopharmaceutical companies AstraZeneca (AZ) and Merck & Co. (MSD)

AstraZeneca, MSD raise prostate cancer awareness with ‘Never Miss’ campaign

https://pharmaphorum.com/news/astrazeneca-msd-raise-prostate-cancer-awareness-with-never-miss-campaign/

News/ News/ Oncology

Pharma M&A rumour mill grinds out Mirati’s name again

Phil Taylor Amgen, KRAS, Lumakras, M&A, Merck & Co, Mirati 0 Comment

Mirati Therapeutics is the subject of takeover speculation in the biopharma sector once again, as it waits for

Pharma M&A rumour mill grinds out Mirati’s name again

https://pharmaphorum.com/news/pharmas-ma-rumour-mill-grinds-out-miratis-name-again/

Market Access/ News/ News/ News/ News/ Oncology/ Patients

Opdivo backed by NICE for rare gastro-oesophageal cancers

Phil Taylor Bristol-Myers Squibb, gastric cancer, HEOR, immuno-oncology, Keytruda, Merck & Co, oesophageal cancer, Oncology, Opdivo 0 Comment

Bristol-Myers Squibb’s Opdivo has been recommended as a treatment for around 3,000 people with rare forms of gastro-oesophageal

Opdivo backed by NICE for rare gastro-oesophageal cancers

https://pharmaphorum.com/news/opdivo-backed-by-nice-for-rare-gastro-oesophageal-cancers/

News/ News/ News/ Oncology/ R&D

Merck bulks up in haematology, buying Imago for $1.35bn

Phil Taylor bomedemstat, Haematology, Imago BioSciences, M&A, Merck & Co, Oncology 0 Comment

While its fabled takeover of Seagen is yet to materialise, Merck & Co has continued to bolster its

Merck bulks up in haematology, buying Imago for $1.35bn

https://pharmaphorum.com/news/merck-bulks-up-again-buying-imago-for-1-35bn/

Market Access/ News/ News

GSK, J&J, and AZ head this year’s access to medicines ranking

Phil Taylor AbbVie, Access to Medicines Index, AstraZeneca, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, market access, Merck & Co 0 Comment

The 2022 edition of the Access to Medicine Index (ATMI) – which places the top 20 pharma companies

GSK, J&J, and AZ head this year’s access to medicines ranking

https://pharmaphorum.com/news/gsk-jj-and-az-head-this-years-access-to-medicines-ranking/

Trending

Merck & Co

Login